JDRF Visits New York Stock Exchange for National Diabetes Awareness Month; President and Chief Executive Officer Jeffrey Brewer Rings The Closing BellSM
Joana Casas, JDRF
NEW YORK – On Tuesday, November 22, 2011, JDRF leadership, staff, and volunteers visited the New York Stock Exchange to celebrate National Diabetes Awareness Month and help raise awareness of type 1 diabetes, its signs and symptoms, and garner support for research that will prevent, better treat, and ultimately cure the disease. Jeffrey Brewer, president and CEO of JDRF, was on hand to ring The Closing Bell at 4:00 p.m. ET.
Type 1 diabetes (T1D) is an autoimmune disease in which a person’s pancreas stops producing insulin, a hormone that enables people to get energy from food. Every year, more than 30,000 new cases of T1D are diagnosed – that’s 80 people per day. T1D affects as many as 3 million children and adults in the U.S. alone. According to the Centers for Disease Control (CDC), both type 1 and type 2 diabetes affects some 26 million people in the U.S. (8.3% of the U.S. population) and costs the U.S. economy $174 billion annually.
Many important developments in T1D research have resulted from JDRF funding, as well as its many partnerships and public awareness efforts. The progress has been impactful – JDRF is funding research that addresses everything to cure, treat, and prevent T1D. JDRF is also leading the development of a closed-loop artificial pancreas system – an automated system that combines a continuous glucose monitor (CGM) and an insulin pump with sophisticated computer software to provide just the right amount of insulin at just the right time. The artificial pancreas will be a revolutionary advance in diabetes care, and JDRF is working to ensure that its development and availability to patients is not delayed by unnecessary regulatory roadblocks.
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.
Since its founding in 1970, JDRF has awarded more than $1.7 billion to diabetes research. Past JDRF efforts have helped to significantly advance the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. More than 80 percent of JDRF’s expenditures directly support research and research-related education.